Cargando…

Recent survival trends in diffuse large B‐cell lymphoma––Have we made any progress beyond rituximab?

BACKGROUND: Population‐based studies previously showed an improvement in overall survival (OS) for patients with diffuse large B‐cell lymphoma (DLBCL) who received chemoimmunotherapy with rituximab. However, there is limited data (especially at the population level) that show a similar trend in OS i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Epperla, Narendranath, Vaughn, John L., Othus, Megan, Hallack, Abrahao, Costa, Luciano J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7402846/ https://www.ncbi.nlm.nih.gov/pubmed/32558356 http://dx.doi.org/10.1002/cam4.3237

Ejemplares similares

Racial and ethnic differences in the utilization of autologous transplantation for lymphoma in the United States
por: Vaughn, John L., et al.
Publicado: (2021)

Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study
por: Vaughn, John L., et al.
Publicado: (2023)

Emerging therapies in mantle cell lymphoma
por: Hanel, Walter, et al.
Publicado: (2020)

Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies
por: Hanel, Walter, et al.
Publicado: (2021)

Nonbiological factors affecting outcomes in adolescents and young adults with lymphoma
por: Dhir, Aditi, et al.
Publicado: (2023)

The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B‐cell lymphoma
por: Habbous, Steven, et al.
Publicado: (2020)

Lymphoma: streamlining follow ups
por: Hallack Neto, Abrahão Elias
Publicado: (2013)

The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?
por: Chan, J K, et al.
Publicado: (2008)

Sixty years trying to define the malaria burden in Africa: have we made any progress?
por: Snow, Robert W
Publicado: (2014)

Maintenance rituximab in Veterans with follicular lymphoma
por: Halwani, Ahmad S., et al.
Publicado: (2020)

A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B‐cell lymphoma in the rituximab era
por: Ishikawa, Eri, et al.
Publicado: (2018)

Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib
por: Denlinger, Nathan M, et al.
Publicado: (2018)

Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era
por: de Oliveira Costa, Renata, et al.
Publicado: (2016)

Management of classical Hodgkin lymphoma: a look at up to date evidence and current treatment approaches
por: Hanel, Walter, et al.
Publicado: (2022)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
por: Jain, Neeraj, et al.
Publicado: (2023)

Monoclonal Antibodies in the Treatment of Diffuse Large B-Cell Lymphoma: Moving beyond Rituximab
por: Papageorgiou, Sotirios G., et al.
Publicado: (2022)

Rituximab maintenance therapy of follicular lymphoma in clinical practice
por: Dührsen, Ulrich, et al.
Publicado: (2018)

Role of radiation therapy in primary breast diffuse large B‐cell lymphoma in the Rituximab era: a SEER database analysis
por: Liu, Pan‐pan, et al.
Publicado: (2018)

What have we learned?
por: Rodgers, Peter, et al.
Publicado: (2021)

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
por: Zhang, Peng‐Fei, et al.
Publicado: (2020)

Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy
por: Suzuki, Tomotaka, et al.
Publicado: (2021)

Have We Any Cholagogues?—Alumni Prize Essay
por: Fuller, George N.
Publicado: (1874)

Differential expression of miRNAs as biomarkers for predicting the outcomes of diffuse large B-cell lymphoma patients
por: Hu, Maogui, et al.
Publicado: (2021)

Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma
por: Epperla, Narendranath, et al.
Publicado: (2017)

Iatrogenic Cushing syndrome and adrenal insufficiency during concomitant therapy with ritonavir and fluticasone
por: Epperla, Narendranath, et al.
Publicado: (2015)

Chronic lymphocytic leukaemia/small lymphocytic lymphoma treatment with rituximab and high‐dose methylprednisolone, revisited
por: Vagos Mata, Ana, et al.
Publicado: (2021)

Biomarkers in critical illness: have we made progress?
por: Honore, Patrick M, et al.
Publicado: (2016)

Swine flu-have we learnt any lesson from the past?
por: Yadav, Sankalp, et al.
Publicado: (2015)

Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study
por: Fleming, Megan, et al.
Publicado: (2022)

Sjögren’s syndrome and Neuromyelitis Optica spectrum disorders (NMOSD) – a case report and review of literature
por: Jayarangaiah, Apoorva, et al.
Publicado: (2014)

An unusual occurrence: a case of venous thromboembolism in pregnancy associated with heterotaxy syndrome
por: Epperla, Narendranath, et al.
Publicado: (2015)

Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy
por: Sircar, Anuvrat, et al.
Publicado: (2020)

β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway
por: Hu, Tonglin, et al.
Publicado: (2020)

Choosing Wisely® in Hematology: Have We Made a Difference?
por: Hilal, Talal, et al.
Publicado: (2020)

Women's mental health: What progress have we made?
por: Herrman, H.
Publicado: (2021)

Response‐adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first‐line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
por: Peñalver, Francisco‐Javier, et al.
Publicado: (2019)

Primary breast diffuse large B-cell lymphoma in the era of rituximab
por: Zhang, Na, et al.
Publicado: (2016)

Subcutaneous Rituximab in Follicular Lymphoma, Chronic Lymphocytic Leukemia, and Diffuse Large B-Cell Lymphoma
por: Yelvington, Bradley J.
Publicado: (2018)

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2022)

MicroRNA-142 is mutated in about 20% of diffuse large B-cell lymphoma
por: Kwanhian, Wiyada, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bqe2baiktjcuvkbralvro7lu6v